Prophylactic role of tixagevimab/cilgavimab for COVID-19 in newly transplanted kidney recipients: Single-center experience and review of literature

doi:10.5500/wjt.v15.i4.100041

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 4

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (531)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

HTML

140

Figures (1-1)

Tables (1-2)

Sum=227

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

228

Sum=275

Dec 18, 2025 (publication date) through Feb 27, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Transplant. Dec 18, 2025; 15(4): 100041
Published online Dec 18, 2025. doi: 10.5500/wjt.v15.i4.100041

Prophylactic role of tixagevimab/cilgavimab for COVID-19 in newly transplanted kidney recipients: Single-center experience and review of literature

Beatrice P Concepcion, Rachel C Forbes, Amna Gul, Kellie Spence, Rachael Simard, Cassandra Bruns, Dhruv Ahuja, Alissar El Chediak

Alissar El Chediak, Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, United States

Dhruv Ahuja, Department of Medicine, Indira Gandhi Hospital, New Delhi 110077, India

Cassandra Bruns, Rachael Simard, Kellie Spence, Kidney and Pancreas Transplant Program, Vanderbilt Transplant Center, Vanderbilt University Medical Center, Nashville, TN 37232, United States

Amna Gul, Department of Medicine, Aga Khan University, Karachi 74800, Pakistan

Rachel C Forbes, Division of Kidney and Pancreas Transplantation, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, United States

Beatrice P Concepcion, Department of Medicine, Section of Nephrology, University of Chicago, Chicago, IL 60637, United States

Co-first authors: Alissar El Chediak and Dhruv Ahuja.

Author contributions: El Chediak A, Ahuja D and Concepcion BP were responsible for conception or design of the work, acquisition, analysis, and interpretation of data for the work, drafting the work, final approval of the version to be published; Bruns C, Simard R, Spence K, Gul A, Forbes RC were responsible for acquisition of data for the work, revising it critically for important intellectual content, final approval of the version to be published.

Institutional review board statement: The Vanderbilt University Institutional Review Board (IRB No. 210132) approved the study.

Informed consent statement: Requirement for informed consent was waived by the Institutional Review Board due to minimal risk to participants.

Conflict-of-interest statement: The authors declare no conflict-of-interest.

STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

Data sharing statement: No additional data are available.

Corresponding author: Beatrice P Concepcion, MD, Associate Professor, Department of Medicine, Section of Nephrology, University of Chicago, 5841 S. Maryland Ave MC 5100, Chicago, IL 60637, United States. beatrice.concepcion@bsd.uchicago.edu

Received: August 5, 2024
Revised: February 23, 2025
Accepted: April 16, 2025
Published online: December 18, 2025
Processing time: 470 Days and 12.1 Hours

Core Tip

Core Tip: This study reports on the use of tixagevimab/cilgavimab in newly transplanted kidney recipients. There were no adverse events related to the drug, and a 12.5% breakthrough infection rate, 4.5% hospitalization rate, and no deaths. The results suggest reassuring outcomes in newly transplanted kidney recipients who received tixagevimab/cilgavimab 300 mg/300 mg as prevention for coronavirus disease 2019 during the omicron wave. A systematic literature review of studies reporting outcomes of solid organ transplant recipients who received tixagevimab/cilgavimab found that the drug was well tolerated and a higher dose (300 mg/300 mg) was more protective against breakthrough infections and hospitalization than the lower dose (150 mg/150 mg).